A systematic review for the efficacy of coenzyme Q10 in patients with chronic kidney disease

Xu, Yongxing; Yang, Gangyi; Zuo, Xiaowen; Gao, Jianjun; Han, Enhong; Liu, Juan; Wang, Yan; Yan, Hong

doi:10.1007/s11255-021-02838-2

Cited by 6 publications

(2 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SQ10 is the most effective treatment superior to the effect of Silymarin singly or combined (Table 3). Previous studies showed CoQ10 to be of potential use as a treatment in diseases in which oxidative stress is a hallmark and reported its beneficial effects in chronic diseases treatment [65][66][67][68].CoQ10 is known for a long time as a potent antioxidant, acting as a primary scavenger of free radicals or in the regeneration of tocopherol [66]. Previously published reports studied the antioxidant capability of its pharmaceutical forms using higher doses and confirmed the oxidative stress suppressing effect of Co Q10 [41, 42,65].…”

Section: Discussionmentioning

confidence: 99%

Biochemical and molecular study on the beneficial effect of Solubilized coenzyme Q10 on thioacetamide-induced liver fibrosis in adult male rats

Abd-Elmoniem

Zaki²

2021

Egypt. J. Chem.

View full text Add to dashboard Cite

The present work aimed to evaluate the combined therapeutic effect of both solubilized Coenzyme Q10 and Silymarin on thioacetamide (TAA) induced liver injury. A total of thirty adult male albino rats, weighing 200±10 g were allocated into five groups. Hepatic injury was induced by Thioacetamide (TAA) 20 mg/ kg b wt for 28 days by intraperitoneal injection twice a week. On the other hand, solubilized Coenzyme Q10 (20 mg/kg) & Silymarin (50 mg/kg) were taken orally for 28 days. Upon using the aspartate and platelet ratio index (APRI) & aspartate aminotransferase-alanine aminotransferase ratio (AAR), the TAA group recording the highest values while treatments using Coenzyme Q10 and or Silymarin could decrease theirs values near the control one. However, solubilized CoQ10 could attenuate liver injury induced by TAA via balanced oxidative stress symbols (GSH, GSSG), NO level, and down-regulation gene expression of fibrotic markers TGF-β, collagen-1α, and, TIMP1 as well as enhanced the expression for MMP2 and cytochrome P 450 (CYP 2E1& CYP 3A2). Collectively, solubilized CoQ10 singly or combined with Silymarin showed higher therapeutic impacts more than or equivalents to Silymarin singly treatment for liver fibrosis induced by TAA.

show abstract

Section: Discussionmentioning

confidence: 99%

Biochemical and molecular study on the beneficial effect of Solubilized coenzyme Q10 on thioacetamide-induced liver fibrosis in adult male rats

Abd-Elmoniem

Zaki²

2021

Egypt. J. Chem.

View full text Add to dashboard Cite

show abstract

“…MitoQ can also attenuate inflammation by reducing leukotriene (LT) B4 and myeloperoxidase (MPO) [ 144 ]. Studies have reported that the synergism between MitoQ and CoQ10 supplements can mildly suppress mitochondrial ROS levels, suggesting that MitoQ alone could be more effective than CoQ10 [ 145 , 146 ]. The renin–angiotensin system (RAS) activation is commonly present in CKD.…”

Section: Pathology Of Aki To Ckd Transitionmentioning

confidence: 99%

Mitochondrial Oxidative Metabolism: An Emerging Therapeutic Target to Improve CKD Outcomes

Mapuskar,

Vasquez-Martinez,

Mayoral-Andrade

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Chronic kidney disease (CKD) predisposes one toward end-stage renal disease (ESRD) and its associated morbidity and mortality. Significant metabolic perturbations in conjunction with alterations in redox status during CKD may induce increased production of reactive oxygen species (ROS), including superoxide (O2−) and hydrogen peroxide (H2O2). Increased O2− and H2O2 may contribute to the overall progression of renal injury as well as catalyze the onset of comorbidities. In this review, we discuss the role of mitochondrial oxidative metabolism in the pathology of CKD and the recent developments in treating CKD progression specifically targeted to the mitochondria. Recently published results from a Phase 2b clinical trial by our group as well as recently released data from a ROMAN: Phase 3 trial (NCT03689712) suggest avasopasem manganese (AVA) may protect kidneys from cisplatin-induced CKD. Several antioxidants are under investigation to protect normal tissues from cancer-therapy-associated injury. Although many of these antioxidants demonstrate efficacy in pre-clinical models, clinically relevant novel compounds that reduce the severity of AKI and delay the progression to CKD are needed to reduce the burden of kidney disease. In this review, we focus on the various metabolic pathways in the kidney, discuss the role of mitochondrial metabolism in kidney disease, and the general involvement of mitochondrial oxidative metabolism in CKD progression. Furthermore, we present up-to-date literature on utilizing targets of mitochondrial metabolism to delay the pathology of CKD in pre-clinical and clinical models. Finally, we discuss the current clinical trials that target the mitochondria that could potentially be instrumental in advancing the clinical exploration and prevention of CKD.

show abstract

The Role of Coenzyme Q10 Supplementation in the Treatment of Diabetes, Hyperlipidemia, and Metabolic-Associated Liver Disease: An Updated Overview of Clinical Implications

Heshmat-Ghahdarijani,

Rabiee Rad,

Nasr

et al. 2024

Curr Treat Options Cardio Med

View full text Add to dashboard Cite

A systematic review for the efficacy of coenzyme Q10 in patients with chronic kidney disease

Cited by 6 publications

References 67 publications

Biochemical and molecular study on the beneficial effect of Solubilized coenzyme Q10 on thioacetamide-induced liver fibrosis in adult male rats

Biochemical and molecular study on the beneficial effect of Solubilized coenzyme Q10 on thioacetamide-induced liver fibrosis in adult male rats

Mitochondrial Oxidative Metabolism: An Emerging Therapeutic Target to Improve CKD Outcomes

The Role of Coenzyme Q10 Supplementation in the Treatment of Diabetes, Hyperlipidemia, and Metabolic-Associated Liver Disease: An Updated Overview of Clinical Implications

Contact Info

Product

Resources

About